BioCentury | Mar 14, 2019
Company News

Orphan Drug designation for Espero's long-acting anticoagulant

...approves therapies for ESRD patients with AF. Tecarfarin is an oral long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...
...Jacksonville, Fla.) said the compound is Phase III-ready. Elizabeth S. Eaton, Staff Writer tecarfarin (ati-5923) Espero Biopharma Inc. Vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | Oct 19, 2015
Company News

Armetheon, Lee’s Pharmaceutical Holdings Ltd. deal

...trial of tecarfarin as an anticoagulant. The product is an oral long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | Feb 6, 2015
Financial News

Armetheon raises $24.3M in series B

...open-label Phase III trial next half of anticoagulant tecarfarin, a long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 ( VKORC1...
BioCentury | May 5, 2014
Clinical News

Tecarfarin: SPA received

...Tecarfarin (formerly ATI-5923 ) Business: Cardiovascular Molecular target: Vitamin K epoxide reductase complex subunit 1 (VKORC1) Description: Long-acting inhibitor of vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | Nov 25, 2013
Clinical News

Warfarin: Phase III data

...were genotyped for the cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | Nov 20, 2013
Top Story

FDA approves first next-gen sequencer

...clinical use. In an cytochrome P450 family 2 subfamily C polypeptide 9 (CYP2C9) and vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | Jul 2, 2012
Clinical News

INFINITI CYP2C19 Assay regulatory update

...variants in the CYP2C19 gene, while the warfarin assay identifies patients with CYP2C9 and vitamin K epoxide reductase complex subunit 1 (VKORC1...
BioCentury | May 23, 2011
Company News

PharmiGene, University of Washington deal

...methods to determine proper dosing of anti-coagulant warfarin. PharmiGene is now the global licensee of VKORC1-1639...
BioCentury | Apr 25, 2011
Clinical News

Verigene Warfarin Metabolism Nucleic Acid Test regulatory update

...diagnostic, which runs on the company's automated Verigene System, identifies variants of the CYP2C9 and VKORC1...
BioCentury | Mar 14, 2011
Clinical News

Warfarin GenoStat Test update

...Genetic Diagnostics Inc. , Bothell, Wash. Product: Warfarin GenoStat Test Business: Diagnostic Molecular target: Vitamin K epoxide reductase complex subunit 1 (VKORC1...
Items per page:
1 - 10 of 29